Helsinki-based biotech NADMED has secured €3.5 million in a Series A funding round to introduce its NAD tests, which measure all four forms of vitamin B3 in the body, to the US and international markets. The funding round was led by Nordic Science Investments (NSI) and saw participation from Voima Ventures, University of Helsinki Funds, and several business angels.
- Founded in 2022 by Jari Närhi and Jana Buzkova, NADMED develops nicotinamide adenine dinucleotide (NAD) measurement technology, which aims to assist physicians in developing more precise and tailored treatments for diverse diseases.
- NADs and glutathiones are essential for energy synthesis, cell repair, and development. Abnormalities in these substances can lead to age-related health problems such as metabolic disorders, cancer, heart disease, cognitive disorders, and muscle atrophy.
- The technology measures all four forms of vitamin B3, known as NADs, and glutathione directly from fresh blood within hours, offering the highest accuracy available. It uses precise colorimetric quantification, even with a small blood sample, to analyze these substances. NADMED offers CE-marked NAD testing kits to clinical laboratories and research facilities to support drug development, clinical needs, and research.
“In the coming years, metabolism will be the hottest topic in medicine and biology, especially when applied to personalized health and disease understanding. In this dawning age of metabolism, NAD will be the new DNA,” CEO and co-founder at NADMED, Jari Närhi, stated.
- As of today, NADMED serves clients across 27 countries, including clinical laboratories, universities, research institutions, and pharmaceutical companies such as Synlab, Newcastle University, the NIH, and Clene Nanomedicine.
Details of the deal
- Nordic Science Investments (NSI) led the investment in NADMED. As a venture capital firm, NSI supports universities and founders from pre-seed to Series A stages across the Nordic and Baltic regions.
“Investing in NADMED was a compelling choice for us, driven by the exceptional expertise of Professor Anu Suomalainen Wartiovaara, a globally recognized leader in metabolic disorders. For investors, the company’s diverse target market not only provides robust risk mitigation but also presents exciting growth opportunities across multiple sectors,” Founding Partner at NSI, Alexandra Gylfe, commented.
- The fresh funding also saw participation from Helsinki-based Voima Ventures and University of Helsinki Funds, from several business angels, and a grant from Business Finland.
- With the capital raised, NADMED plans to expand internationally and introduce its technology in the US.
